News: Plus Therapeutics Announces Plans for Treating Pediatric Brain Cancer
Pediatric Brain Cancer:
U.S. Phase 1 Clinical Trial
Not Yet Recruiting
Cancer: U.S. Phase
1 Clinical Trial
Not Yet Recruiting
Not Yet Recruiting
Pediatric brain cancer is relatively rare. However, cancer is the leading cause of death by disease among children in the U.S. Brain and spinal cord tumors are the 2nd most common cancers in children, accounting for ~26% of childhood cancers.
Plus Therapeutics is developing the Rhenium (186Re) Obisbemeda radiotherapeutic for the treatment of rare, frequently fast-growing pediatric brain and spinal cord tumors with a poor prognosis – ependymoma and high-grade glioma (HGG). The ReSPECT-PBC (Pediatric Brain Cancer) U.S. Phase 1 Clinical Trial is planned to start in 2023.
“Children with brain tumors have limited options & 186RNL delivered with a minimally invasive procedure could be an important new potential option for these patients.”
Michael G. DeCuypere, MD, PhD, FAANS
Northwestern University Feinberg School of Medicine
Ashley S. Plant, M.D.
Lurie Children’s Hospital of Chicago
SPECIALTIES: CANCER & BLOOD DISORDERS
Ashley S. Plant, M.D. is an attending physician in neuro-oncology at Ann and Robert H. Lurie Children’s Hospital of Chicago and is an Assistant Professor of Pediatrics at Northwestern University. Dr. Plant received her medical degree from Stanford University School of Medicine. She completed her pediatrics residency at University of California, Los Angeles and her pediatric hematology/oncology fellowship at Dana Farber Cancer Institute/Boston Children’s Hospital. She completed additional training in neuro-oncology at Dana Farber Cancer Institute. Her research focus includes immunotherapy and the immune microenvironment as well as early phase clinical trial design for pediatric brain tumors.
Please visit this website regularly for updates as new locations are added.
Lurie Children’s Hospital
What Can You Do Next?
Participating in a clinical trial is an important decision. If you believe this clinical trial might be a good fit and are interested in participating, please take the next step to see if you are eligible.
July 27, 2023
- Presentations titled: [LMAP-21] Preliminary Clinical Data in the Phase 1/2a Dose Escalation Trial of Rhenium (186Re) Obisbemeda (186RNL) in Leptomeningeal Metastases (LM): The ReSPECT-LM Trial; [TIPS-23] Safety and Feasibility Results from a Phase 1/2 Clinical Trial of Rhenium (186Re) Obisbemeda (186RNL) in Recurrent Glioma: The ReSPECT-GBM Trial; [TIPS-22] A two-part, Phase 1 study of Rhenium (186Re) Obisbemeda (186RNL) delivered by convection enhanced delivery (CED) for recurrent, refractory, or progressive childhood ependymoma and high-grade glioma (HGG)
June 8, 2023
- Plus Therapeutics announced it will exhibit at both the Society for NeuroOncology’s (SNO) Pediatric Conference, taking place June 22-24, 2023 in Washington, D.C., and the Society of Nuclear Medicine & Molecular Imaging’s (SNMMI) Annual Meeting, taking place June 24-27, 2023 in Chicago, Illinois.
November 19, 2022
- In November 2022, Plus Therapeutics, in collaboration with Lurie Children’s Hospital investigators, anticipates filing an Investigational New Drug (IND) application for a first-in-child Phase 1/2a clinical trial to determine the maximum tolerated dose, safety, tolerability and early efficacy of rhenium (186Re) obisbemeda in supratentorial recurrent or progressive pediatric ependymoma and high-grade glioma (HGG) in up to 24 patients initially. These plans were presented in a poster titled, “A two-part, Phase 1 study of Rhenium-186 NanoLiposome (186RNL) delivered by convection enhanced delivery (CED) for recurrent or progressive childhood ependymoma and high-grade glioma (HGG) [CTNI-19]”.
August 21, 2021
June 10, 2021
2022 SNO Annual Conference: A Two-Part, Phase 1/2a Trial to Determine the Maximum Tolerated Dose, Safety, and Tolerability of Rhenium-186 Nanoliposome (186RNL) in Supratentorial Recurrent Pediatric Ependymoma and High-Grade Glioma: a First-in-Pediatrics Study
Pediatric Neuro-Oncology Research Conference (SNO): A two-part, Phase I study of Rhenium-186 Nanoliposomes (186RNL) delivered by convection enhanced delivery (CED) for recurrent, refractory, or progressive ependymoma and high-grade glioma (HGG)
Note: all external links
- American Brain Tumor Association
- American Cancer Society
- American Childhood Cancer Organization
- Brain Tumor Network
- Dictionary of Cancer Terms
- End Brain Cancer Initiative
- Ependymoma Cancer Research Network
- MedlinePlus (NIH)
- National Brain Tumor Society
- National Cancer Institute
- National Comprehensive Cancer Network
- Pediatric Brain Tumor Foundation
- Support Groups Listing
- The Brain Tumour Charity
- Trial Connect
- Voices Against Brain Cancer